Global  Video

“The world's speediest news portal”
One News Page
> >

Novartis posts eye drug data amid play for Eylea's turf

Reuters India Friday, 10 November 2017
ZURICH (Reuters) - Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.
0
shares
Share on
Facebook
Share on
Twitter
Post on 
Reddit
Share by
Email
 
Source: Wochit Business - < > Embed
News video: Novartis To Enter Eye-Drug Market

▶ Novartis To Enter Eye-Drug Market 00:43

Novartis is gearing up to shake up a huge eye-drug market. Data presented Friday at the American Academy of Opthamology annual conference, revealed that drug company Novartis' drug brolucizumab was as comparable ot in some cases better than Eylea. Eylea is an existing drug to treat a condition called...

You Might Like


Recent related news

Regeneron CEO says fears over Eylea 'greatly exaggerated'

(Reuters) - Fears of the demise of blockbuster eye drug Eylea were "greatly exaggerated," Regeneron Pharmaceuticals Inc's chief executive said on Thursday, after...
Reuters - Health

Community Healthcare System Integrates Indiana Prescription Drug Monitoring Program Data into Epic Electronic Health Records with Appriss Health's PMP Gateway

Louisville, KY, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Appriss Health, provider of the most comprehensive platform for substance use disorder (SUD) in the U.S., today...
GlobeNewswire - Press Releases


Tweets about this


Other recent news in Health

Fathers may pass OVARIAN CANCER risk to daughtersPot Pharm: Booming CANADA weed sector plots next-wave medicines
OLYMPICS: Two Swiss freestyle skiers contract norovirus - Swiss teamRESEARCH lacking on medical marijuana, new prescription guideline suggests
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2018 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+